Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low serum alanine aminotransferase (ALT) levels, a marker for sarcopenia, are linked to poorer survival in renal cell carcinoma (RCC) patients. This finding may help personalize treatment decisions for RCC survivors.
Area Of Science
- Oncology
- Geriatrics
- Biochemistry
Background
- Sarcopenia, characterized by muscle mass and function loss, is linked to frailty and reduced survival in cancer patients.
- Low serum alanine aminotransferase (ALT) levels are a biomarker for sarcopenia and have been associated with frailty and poor survival in various cancers.
Purpose Of The Study
- To investigate the association between low ALT levels and survival outcomes in renal cell carcinoma (RCC) patients and survivors.
Main Methods
- Retrospective analysis of 1830 RCC patients and survivors.
- Sarcopenia defined by ALT < 17 IU/L.
- Statistical analysis including univariate and multivariate models.
Main Results
- 44.3% of patients had low ALT (< 17 IU/L).
- Low ALT patients were older, with lower BMI, hemoglobin, and higher creatinine and platelet-to-lymphocyte ratios.
- Low ALT was associated with a 72% increase in mortality (univariate) and a 27% increase (multivariate).
Conclusions
- Low ALT levels, indicative of sarcopenia, are associated with shortened survival in RCC patients and survivors.
- This biomarker could aid in optimizing individualized treatment strategies for RCC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.